Y-mAbs Therapeutics (NASDAQ:YMAB) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) issued its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02), RTT News reports. The company had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. During the same period last year, the firm earned ($0.18) EPS. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Trading Down 0.5 %

NASDAQ:YMAB traded down $0.07 during trading hours on Friday, hitting $15.48. 580,428 shares of the stock were exchanged, compared to its average volume of 330,577. The firm’s fifty day moving average price is $14.11 and its 200 day moving average price is $13.17. The company has a market cap of $689.94 million, a P/E ratio of -27.64 and a beta of 0.68. Y-mAbs Therapeutics has a 52-week low of $4.69 and a 52-week high of $20.90.

Insider Activity

In other news, insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the sale, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at approximately $449,514. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the transaction, the insider now owns 97,681 shares in the company, valued at $1,315,763.07. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock worth $1,338,100 over the last ninety days. Corporate insiders own 22.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on YMAB. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Morgan Stanley cut their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Canaccord Genuity Group restated a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Finally, Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.